Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$46.53 USD
+2.82 (6.45%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $46.48 -0.05 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Janux Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 9 | 4 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 8 | 9 | 4 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 81 | 76 | 37 | 5 | 4 |
Income After Depreciation & Amortization | -73 | -67 | -33 | -5 | -4 |
Non-Operating Income | 15 | 4 | 0 | -2 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -58 | -63 | -33 | -7 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -58 | -63 | -33 | -7 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -58 | -63 | -33 | -7 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -79 | -68 | -33 | -5 | -4 |
Depreciation & Amortization (Cash Flow) | -6 | -1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -73 | -67 | -33 | -5 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.02 | 41.47 | 23.53 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.32 | -1.52 | -1.39 | NA | NA |
Diluted Net EPS (GAAP) | -1.32 | -1.52 | -1.39 | -7.41 | NA |
Fiscal Year end for Janux Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 8.90 | 1.25 | 2.46 | 2.52 | 1.06 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 8.90 | 1.25 | 2.46 | 2.52 | 1.06 |
SG&A, R&D, and Dept/Amort Expenses | 22.72 | 21.41 | 18.60 | 18.33 | 21.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | -13.82 | -20.16 | -16.14 | -15.81 | -20.74 |
Non-Operating Income | 7.86 | 5.40 | 4.38 | 4.25 | 3.24 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.96 | -14.76 | -11.76 | -11.57 | -17.51 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.96 | -14.76 | -11.76 | -11.57 | -17.51 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.96 | -14.76 | -11.76 | -11.57 | -17.51 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 54.45 | 49.05 | 46.68 | 45.71 | 41.84 |
Diluted EPS Before Non-Recurring Items | -0.11 | -0.30 | -0.25 | -0.25 | -0.42 |
Diluted Net EPS (GAAP) | -0.11 | -0.30 | -0.23 | -0.25 | -0.42 |